martes, 2 de enero de 2024

Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial Leng et al.

https://www.thelancet.com/journals/lanrhe/home

No hay comentarios:

Publicar un comentario